Cargando…

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Maggi, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057109/ https://www.ncbi.nlm.nih.gov/pubmed/36992424 http://dx.doi.org/10.3390/v15030715

Ejemplares similares

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
por: Focosi, Daniele, et al.
Publicado: (2023)

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Recombination in Coronaviruses, with a Focus on SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
por: Focosi, Daniele, et al.
Publicado: (2023)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 recombinant XN, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

TTV viral load as a predictor of antibody response to SARS COV-2 vaccination
por: Focosi, Daniele, et al.
Publicado: (2023)

Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers.
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Preoperative SARS-CoV-2 screening: Can it really rule out COVID-19?
por: Lother, Sylvain A.
Publicado: (2020)

Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes
por: Maggi, Fabrizio, et al.
Publicado: (2021)

Serology Testing for SARS-CoV-2: Benefits and Challenges
por: Jalali Nadoushan, Mohammadreza, et al.
Publicado: (2020)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy
por: Baj, Andreina, et al.
Publicado: (2021)

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
por: Baj, Andreina, et al.
Publicado: (2021)

Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects
por: Spezia, Pietro Giorgio, et al.
Publicado: (2022)

Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: A case report and literature update
por: Franchini, Massimo, et al.
Publicado: (2023)

From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses
por: Focosi, Daniele
Publicado: (2023)

Approaching Challenges Posed by SARS-CoV-2 Genetic Variants
por: de la Fuente, José
Publicado: (2022)

Development, Safety, Issues, and Challenges of the SARS-CoV-2 Vaccine
por: Matsuzaka, Yasunari, et al.
Publicado: (2023)

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
por: Focosi, Daniele, et al.
Publicado: (2022)

The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants
por: Choi, Hosoon, et al.
Publicado: (2021)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

How ADA methodology informs SARS-CoV-2 assay development
por: Becker, Caroline
Publicado: (2020)

SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead
por: Baldo, Vincenzo, et al.
Publicado: (2021)

Viral pandemics and oral health: Lessons learned from HIV to SARS-CoV-2
por: Patton, Lauren L.
Publicado: (2021)

Initiation of Antiviral Treatment in SARS‐CoV2: Modeling Viral Dynamics and Drug Properties
por: Rosenbloom, Daniel Scholes, et al.
Publicado: (2020)

The practical challenges of making clinical use of the quantitative value for SARS-CoV-2 viral load across several dynamics
por: Mathers, Amy J
Publicado: (2020)

How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2
por: Mehdizadeh, Ali Reza, et al.
Publicado: (2021)

Ten simple rules for responsible big data research
por: Zook, Matthew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a5h71dcrb6tlla0a90sors8c5q